Comparative Pharmacology
Head-to-head clinical analysis: CLOVIQUE versus PLETAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOVIQUE versus PLETAL.
CLOVIQUE vs PLETAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLOVIQUE is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), a pro-inflammatory cytokine. By blocking IL-6 from binding to its receptor, it reduces inflammation and immune responses.
Cilostazol inhibits phosphodiesterase III (PDE3), increasing cAMP levels in platelets and vascular smooth muscle, leading to platelet inhibition and vasodilation.
10 mg orally once daily.
100 mg orally twice daily, administered at least 30 minutes before or 2 hours after meals.
None Documented
None Documented
Terminal half-life of 22-30 hours; allows once-daily dosing with steady-state achieved in 5-7 days
Terminal half-life of cilostazol is approximately 11-13 hours; for active metabolites 3,4-dehydro-cilostazol (about 4-6 times more active) half-life is similar. Steady state achieved within a few days.
Renal: 65-75% unchanged; biliary/fecal: 20-25% as metabolites
Renal (approximately 77% as metabolites, <1% unchanged); fecal (approximately 18%)
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent